A share price of Beam Therapeutics Inc [BEAM] is currently trading at $31.22, down -2.59%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BEAM shares have gain 13.32% over the last week, with a monthly amount glided 16.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on October 09, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $41. Previously, BofA Securities upgraded its rating to Buy on March 28, 2025, and kept the price target unchanged to $42. On March 10, 2025, upgrade upgraded it’s rating to Sector Outperform but maintained its price target of $40 on the stock. Cantor Fitzgerald upgraded its rating to an Overweight. Leerink Partners upgraded its rating to an Outperform and raised its price target to $39 on November 06, 2024. In a note dated July 23, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $80 on this stock.
Beam Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $13.52 and $36.44. Currently, Wall Street analysts expect the stock to reach $34.67 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $31.22 at the most recent close of the market. An investor can expect a potential return of 11.05% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
Trailing Twelve Months sales for Beam Therapeutics Inc [NASDAQ:BEAM] were 55.70M which represents -32.03% decline. Gross Profit Margin for this corporation currently stands at -6.39% with Operating Profit Margin at -8.37%, Pretax Profit Margin comes in at -7.44%, and Net Profit Margin reading is -7.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.43 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Beam Therapeutics Inc [NASDAQ:BEAM] is 6.02. In addition, the Quick Ratio stands at 6.02 and the Cash Ratio stands at 1.47. Considering the valuation of this stock, the price to sales ratio is 56.88, the price to book ratio is 3.28.
Transactions by insiders
Recent insider trading involved CHRISTINE BELLON, Officer, that happened on Jan 15 ’26 when 18629.0 shares were purchased. Chief Financial Officer, Emany Sravan Kumar completed a deal on Dec 31 ’25 to sell 6294.0 shares. Meanwhile, Chief Legal Officer Bellon Christine sold 1254.0 shares on Dec 31 ’25.
